Top 10 Undervalued Stocks For 2022


AbbVie’s  (ABBV) – Get AbbVie, Inc. Report selloff was overdone after a Sept. 1 setback for its star immunology drug Rinvoq, and the stock remains undervalued, says BMO analyst Gary Nachman.

He has an outperform rating and a $133 price target. The stock recently traded at $106.61, down 0.81%, and has dropped 12% since Aug. 31.

On Sept. 1, the Food and Drug Administration mandated new heart safety and cancer warnings for Rinvoq and other companies’ JAK inhibitor class of medicines.

“Physicians agreed Rinvoq is still likely to get approved for atopic dermatitis (AD), given its overall risk/benefit,” Nachman said. “Even with limited use, it could still be a solid opportunity.”

TheStreet RecommendsPRESS RELEASESBevCanna Announces Product Listings And Purchase Orders From British Columbia Liquor Distribution Branch35 minutes agoPRESS RELEASESPeer-to-Peer Carsharing Market To Surpass $7,225.2 Million Revenue By 2030 Says P&S Intelligence35 minutes agoPRESS RELEASESFarm Equipment Market Share, Size, Trends & Growth 2020- 2024 | 17000 Technavio Reports35 minutes ago


So, “Our sensitivity analysis to already conservative Rinvoq forecasts suggests the selloff has been overdone,” he said.

Top 10 Undervalued Stocks For 2022: Smith & Nephew SNATS, Inc.(SNN)

Smith & Nephew plc develops, manufactures, markets, and sells medical technology products and services worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints; and arthroscopy enabling technologies for healthcare providers, such as fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency wands, electromechanical and mechanical blades, and hand instruments for removing damaged tissue. It also provides trauma and extremities products consisting of internal and external devices used in the stabilization of severe fractures and deformity correction procedures; gynecological instrumentation devices; knee implant products for specialized knee replacement procedures; and hip implant products for reconstruction of the hip joint, as well as various products and technologies to assist in surgical treatment of the ear, nose, and throat. In addition, the company offers advanced wound care products for the treatment of acute and chronic wounds, including leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound devices, including traditional and single-use negative pressure wound therapy and hydrosurgery systems; and biologics and other bioactive technology products for debridement and dermal repair/regeneration. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.


Advisors’ Opinion:

  • [By Stephan Byrd]

    CVB Financial (NASDAQ:CVBF) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Thursday.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on CVB Financial (CVBF)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top 10 Undervalued Stocks For 2022: AcelRx Pharmaceuticals Inc.(ACRX)


AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain in the United States. The company develops ARX-01, a Sufentanil NanoTab PCA system, which completed Phase II clinical trial for acute post-operative pain. The Sufentanil NanoTab PCA system consists of sufentanil, a high therapeutic index opioid; NanoTabs, a non-invasive sublingual dosage form; and a handheld PCA device that enables simple patient-controlled delivery of NanoTabs in the hospital setting and eliminates the risk of programming errors. Its products also include ARX-02, a Sufentanil NanoTab BTP Management System that completed Phase II clinical trial for the treatment of cancer breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which completed Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a ph ysician?s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood, California.


Advisors’ Opinion:

  • [By Keith Speights]

    Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) were sinking by 11.3% as of 10:47 a.m. EST on Friday. The specialty pharmaceutical company announced its fourth-quarter and full-year 2018 results after the market closed on Thursday.

  • [By Shane Hupp]

    TRADEMARK VIOLATION WARNING: “AcelRx Pharmaceuticals (ACRX) Releases Earnings Results, Beats Expectations By $0.05 EPS” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at www.tickerreport.com/banking-finance/4206297/acelrx-pharmaceuticals-acrx-releases-earnings-results-beats-expectations-by-0-05-eps.html.

  • [By George Budwell, Chuck Saletta, and Todd Campbell]

    Armed with this insight, we asked three of our Motley Fool contributors which top small-cap stocks have their attention right now. They named AcelRx Pharmaceuticals (NASDAQ:ACRX),Realogy Holdings (NYSE:RLGY), andRegenxbio Inc. (NASDAQ:RGNX). Read on to find out why.

  • [By Keith Speights]

    Surprises for small biotechs are often of the unpleasant variety. But that wasn’t the case for AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) on Wednesday.

Top 10 Undervalued Stocks For 2022: Arqit Quantum Inc.(ARQQ)


Arqit Limited develops and offers quantum key distribution network. It offers QuantumCloud, an unbreakable software encryption keys, using satellite to deliver quantum information to data centers. The company uses the quantum properties of photons to create unique keys that can be shared between two parties in laser transmissions from a satellite. The company was incorporated in 2017 and is based in London, United Kingdom.

Advisors’ Opinion:

  • [By James Brumley (TMFjbrumley)]

    It took a while to get going, but Arqit Quantum (NASDAQ:ARQQ) shares finally took off following Wednesday morning’s news of a new business agreement. Namely, shares of the UK-based cybersecurity outfit ended today’s session 26.5% higher on the heels of an announcement that it would be exploring network security opportunities with Juniper Networks (NYSE:JNPR).

Top 10 Undervalued Stocks For 2022: Liberty TripAdvisor Holdings, Inc.(LTRPA)

During October 2013, the Board of Directors of Liberty Interactive Corporation and its subsidiaries (“Liberty”) authorized a plan to distribute to the stockholders of Liberty’s Liberty Ventures common stock shares of a newly-formed company, Liberty TripAdvisor Holdings, Inc. (“TripCo” or the “Company”) (the “Trip Spin-Off”). TripCo holds the subsidiaries TripAdvisor, Inc. (“TripAdvisor”) and BuySeasons, Inc., which includes the retail businesses of BuyCostumes.com and Celebrate Express (“BuySeasons”), both of which operate as stand-alone operating entities. Both TripAdvisor and BuySeasons have more revenue in the third quarter, based on a higher travel research period and the Halloween period, respectively, as compared to the other quarters of the year. The Trip Spin-Off was completed on August 27, 2014 and effected as a pro-rata dividend of shares of TripCo to the stockholders of Series A and Series B Liberty Ventures common stock of Liberty.   Advisors’ Opinion:

  • [By Ethan Ryder]

    Engineers Gate Manager LP acquired a new position in Liberty Tripadvisor Holdings Inc Series A (NASDAQ:LTRPA) during the second quarter, Holdings Channel reports. The fund acquired 102,003 shares of the technology company’s stock, valued at approximately $1,642,000.

  • [By Max Byerly]

    Liberty Tripadvisor Holdings Inc Series A (NASDAQ:LTRPA) saw a large increase in short interest during the month of May. As of May 31st, there was short interest totalling 2,070,644 shares, an increase of 47.7% from the May 15th total of 1,402,097 shares. Currently, 2.9% of the company’s stock are short sold. Based on an average daily trading volume, of 839,315 shares, the short-interest ratio is currently 2.5 days.

  • [By Lisa Levin]

    Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPA) shares shot up 30 percent to $12.05 following TripAdvisor Q1 earnings beat.

    Shares of ZAGG Inc (NASDAQ: ZAGG) got a boost, shooting up 26 percent to $14.48 after the company posted better-than-expected Q1 earnings.

  • [By Lisa Levin] Gainers
    Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPA) shares jumped 31.6 percent to $12.18 following TripAdvisor Q1 earnings beat.
    ZAGG Inc (NASDAQ: ZAGG) rose 26.5 percent to $14.55 after the company posted better-than-expected Q1 earnings.
    OPKO Health, Inc. (NASDAQ: OPK) shares gained 25 percent to $4.0234 following Q1 beat.
    Axon Enterprise, Inc. (NASDAQ: AAXN) jumped 23.5 percent to $55.12 following a big Q1 beat. The company raised its fiscal 2018 sales growth guidance from 16-18 percent to 18-20 percent.
    Penn Virginia Corporation (NASDAQ: PVAC) gained 23.3 percent to $59.00 after reporting Q1 results.
    TripAdvisor, Inc. (NASDAQ: TRIP) rose 22.5 percent to $47.51 after the company reported stronger-than-expected results for its first quarter on Tuesday.
    Sears Holdings Corporation (NASDAQ: SHLD) shares surged 21.7 percent to $3.36. Amazon.com's partnership with Sears started in 2017 with an agreement to sell Kenmore-branded appliances online. On Wednesday, the companies announced an extension of their relationship to now include tire delivery and installations.
    EP Energy Corporation (NYSE: EPE) jumped 21.3 percent to $2.68 following Q1 results.
    LendingClub Corporation (NYSE: LC) surged 20.4 percent to $3.395 following better-than-expected Q1 earnings.
    Superior Industries International, Inc. (NYSE: SUP) gained 19 percent to $15.82 after reporting Q1 results.
    Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) shares rose 18.5 percent to $8.13 following Q1 results.
    Twilio Inc. (NYSE: TWLO) rose 18.3 percent to $52.47 after the company posted strong quarterly results.
    Cerus Corporation (NASDAQ: CERS) shares jumped 18.3 percent to $6.47 following quarterly results.
    IEC Electronics Corp. (NYSE: IEC) shares climbed 17 percent to $4.68 after reporting better-than-expected quarterly earnings.
    New Relic, Inc. (NYSE: NEWR) rose 16.8 percent to $90.10 following Q4 results.
    Gulfport Energy Corporation (NASDAQ: GPOR)

Top 10 Undervalued Stocks For 2022: MuniVest Fund, Inc.(MVF)


BlackRock MuniVest Fund, Inc. (the Fund), formerly known as MuniVest Fund, Inc., is a non-diversified, closed-end management investment company. The Fund seeks to provide a high a level of current income exempt from federal income taxes by investing primarily in a portfolio of long-term, investment-grade municipal obligations, the interest on which is exempt from federal income taxes.

BlackRock MuniVest Fund, Inc. may invest in certain securities, whose income return is inversely related to changes in a floating interest rate (inverse floaters). The Fund may invest in swap agreements. The Fund may also purchase and write call and put options. BlackRock MuniVest Fund, Inc.’s investment advisor is BlackRock Advisors, LLC, a wholly owned subsidiary of BlackRock, Inc. The Fund’s sub-advisor is BlackRock Investment Management, LLC.


Advisors’ Opinion:

  • [By Max Byerly]

    BlackRock MuniVest Fund Inc. (NYSEAMERICAN:MVF) declared a monthly dividend on Thursday, September 6th, Wall Street Journal reports. Stockholders of record on Friday, September 14th will be paid a dividend of 0.041 per share by the investment management company on Monday, October 1st. This represents a $0.49 annualized dividend and a dividend yield of 5.57%. The ex-dividend date of this dividend is Thursday, September 13th.

Top 10 Undervalued Stocks For 2022: Canadian Pacific Railway Limited(CP)


Canadian Pacific Railway Limited, through its subsidiaries, operates a transcontinental railway in Canada and the United States. The company provides logistics and supply chain expertise services. It transports bulk commodities, including grain, coal, fertilizers, and sulphur; and intermodal traffic comprising retail goods in overseas containers that can be transported by train, ship, and truck, as well as in domestic containers and trailers that can be moved by train and truck. The company also transports merchandise freight consisting of finished vehicles and automotive parts, chemicals and plastics, crude oil, and forest products, as well as metals, minerals, and consumer products. It provides rail and intermodal transportation services over a network of approximately 13,700 miles serving the business centers of Canada from Montreal, Quebec, to Vancouver, British Columbia, and the United States Northeast and Midwest regions. In addition, the company offers transloading, warehousing, and distribution services of steel products. Canadian Pacific Railway Limited was founded in 1881 and is headquartered in Calgary, Canada.


Advisors’ Opinion:

  • [By George Budwell, Chuck Saletta, and Todd Campbell]

    So, with the biotech space solidly on the comeback trail, we asked three of our Motley Fool contributors which stocks they think are poised to keep churning higher in February and perhaps for the remainder of the year. They suggested Viking Therapeutics (NASDAQ:VKTX), Cambrex (NYSE:CBM), and Sarepta Therapeutics (NASDAQ:SRPT). Here’s why.

  • [By Motley Fool Transcribers]

    Cambrex Corp (NYSE:CBM)Q42018 Earnings Conference CallFeb. 13, 2019, 8:30 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Brian Feroldi]

    In response to reporting of fourth-quarter and full-year quarterly results, shares of Cambrex Corporation (NYSE:CBM), a supplier to the life sciences industry, fell 11% as of 11:10 a.m. EST on Wednesday.

  • [By Logan Wallace]

    Shares of Cambrex Co. (NYSE:CBM) have earned a consensus recommendation of “Hold” from the six brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $60.00.

Leave a Reply

Your email address will not be published.